Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
Ramón García‐Sánz(Centro de Investigación del Cáncer), Carmen Martı́nez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Gabriela Rodrı́guez(Peruvian University of Applied Sciences), Miguel Canales(Hospital Universitario La Paz), Ana Pilar González(Hospital Clínico Universitario de Valencia), Blanca Sánchez‐González(The University of Texas MD Anderson Cancer Center), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Marı́a Dolores Caballero(Complejo Hospitalario de Salamanca), Antonia Rodríguez(Hospital Universitario Reina Sofía), Miriam Moreno(Universitat Autònoma de Barcelona), Javier López(Hospital Universitario Ramón y Cajal), Fátima De la Cruz(Hospital Universitario La Paz), Antonio Gutiérrez(Hospital Universitario Son Dureta), Piñana Luis Jose(Hospital Clínico Universitario de Valencia), Eva Domingo‐Doménech
Cited by 47
Related Papers
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718